Perrigo Company plc (NYSE:PRGO – Get Free Report) announced a quarterly dividend on Friday, November 1st, RTT News reports. Shareholders of record on Friday, November 29th will be paid a dividend of 0.276 per share on Tuesday, December 17th. This represents a $1.10 annualized dividend and a yield of 4.23%.
Perrigo has raised its dividend by an average of 6.7% per year over the last three years and has raised its dividend annually for the last 22 consecutive years. Perrigo has a payout ratio of 34.6% indicating that its dividend is sufficiently covered by earnings. Analysts expect Perrigo to earn $3.12 per share next year, which means the company should continue to be able to cover its $1.10 annual dividend with an expected future payout ratio of 35.3%.
Perrigo Trading Up 1.8 %
Shares of Perrigo stock traded up $0.46 on Friday, reaching $26.09. The company had a trading volume of 1,509,259 shares, compared to its average volume of 1,610,574. The firm’s 50-day moving average price is $26.48 and its two-hundred day moving average price is $27.66. Perrigo has a 1 year low of $23.89 and a 1 year high of $34.60. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.99 and a quick ratio of 1.24.
Analyst Upgrades and Downgrades
Several research analysts recently commented on PRGO shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $42.00 price target on shares of Perrigo in a research note on Monday, September 30th. Jefferies Financial Group reaffirmed a “hold” rating and set a $30.00 price target (down previously from $50.00) on shares of Perrigo in a research note on Monday, September 23rd. StockNews.com cut Perrigo from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Finally, Piper Sandler decreased their target price on Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.00.
Get Our Latest Report on Perrigo
Insider Buying and Selling at Perrigo
In related news, EVP Ronald Craig Janish sold 13,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $29.40, for a total transaction of $382,200.00. Following the transaction, the executive vice president now directly owns 20,553 shares in the company, valued at approximately $604,258.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Perrigo news, EVP Svend Andersen sold 28,300 shares of Perrigo stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $27.75, for a total transaction of $785,325.00. Following the transaction, the executive vice president now directly owns 73,553 shares of the company’s stock, valued at $2,041,095.75. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ronald Craig Janish sold 13,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $29.40, for a total transaction of $382,200.00. Following the completion of the transaction, the executive vice president now owns 20,553 shares in the company, valued at approximately $604,258.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,254 shares of company stock valued at $1,411,969. Corporate insiders own 0.70% of the company’s stock.
Perrigo Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
See Also
- Five stocks we like better than Perrigo
- What is a Secondary Public Offering? What Investors Need to Know
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Manufacturing Stocks Investing
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.